Why, Who, What, Where, When and How to use biosimilar insulins
NHS spending nearly DOUBLES to almost a billion in a decade – nearly one third is spent on Insulins. Biosimilars are comparatively less costly options – do they offer similar efficacy and safety? What are the cost implications? This session will uncover myths and facts about biosimilar insulins.
- Understand what biosimilar insulins are.
- Outline the evidence that supports where the biosimilars can be used
- Define who will benefit from use of biosimilars and when this is best considered.
- Consider how the availability of biosimilar insulin will impact clinical practice and you
*This session is organised and remunerated by Mylan
Wednesday 30 October 2019
12:40 - 13:20
Commissioning & Integrated Care